It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of Incyte's (INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's (BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane.
Incyte press release and poster can be found here.
Seeing a complete response is always a good sign, so while the number of patients treated in the 50 mg cohort is small, there's enough clinical activity here to justify running new combination studies of '360 and the PD-1 inhibitors from Bristol, Merck (MRK) and others.
Incyte shares rebounded big time when the '360 data were announced this afternoon.